Suppr超能文献

中国浙江省台州市耐多药/利福平耐药结核病的诊断与治疗路径

Diagnosis and Treatment Pathway of MDR/RR-TB in Taizhou, Zhejiang Province, China.

作者信息

Lu Jingting, Xu Yuanyuan, Li Zhipeng, Chen Xiaoxiao, Lin Haijiang, Zhao Qi

机构信息

School of Public Health, Fudan University, Shanghai 200032, China.

Key Laboratory of Public Health Safety, Ministry of Education, Shanghai 200032, China.

出版信息

Trop Med Infect Dis. 2023 Jan 21;8(2):79. doi: 10.3390/tropicalmed8020079.

Abstract

This study aims to understand MDR/RR-TB patients' experience from seeking TB-related health care to diagnosis and treatment completion, as well as the social determinants with the waiting time for DST and treatment, pre-treatment attrition, and treatment outcome based on a retrospective cohort study. Univariate and multi-variate logistic regressions were used to analyze the associated factors. The median time of waiting time for DST and treatment was 24.00 and 30.00 days, respectively. Non-residential patients (aOR: 2.89, 95% CI: 1.14-7.70), registered before 2018 (aOR: 19.93, 95% CI: 8.99-48.51), first visited a county-level hospital (aOR: 4.65, 95% CI: 1.08-21.67), sputum smear-negative (aOR: 3.54, 95% CI: 1.28-10.16), and comorbid with pneumoconiosis (aOR: 7.10, 95% CI: 1.23-47.98) had a longer DST delay. The pre-treatment attrition was 26.9% (82/305). Elderly, non-residential patients and patients registered before 2018 were more likely to refuse MDR/RR treatment. However, in housekeeping/unemployment and farmer/fisherman, recurrent patients tended to take therapeutic measures actively. The successful treatment rate was 62.1% (105/169). Elderly, comorbidity with diabetes and sputum smear conversion time >1 month may lead to poorer outcomes. Immediate interventions should be taken to smooth diagnosis and treatment pathways and improve the social protections further so as to encourage patients to cooperate with the treatment actively.

摘要

本研究旨在通过一项回顾性队列研究,了解耐多药/利福平耐药结核病(MDR/RR-TB)患者从寻求结核病相关医疗服务到诊断及完成治疗的经历,以及与药敏试验(DST)和治疗等待时间、治疗前脱落及治疗结果相关的社会决定因素。采用单因素和多因素逻辑回归分析相关因素。DST和治疗的中位等待时间分别为24.00天和30.00天。非本地居住患者(调整后比值比[aOR]:2.89,95%置信区间[CI]:1.14-7.70)、2018年前登记的患者(aOR:19.93,95%CI:8.99-48.51)、首次就诊于县级医院的患者(aOR:4.65,95%CI:1.08-21.67)、痰涂片阴性的患者(aOR:3.54,95%CI:1.28-10.16)以及合并尘肺病的患者(aOR:7.10,95%CI:1.23-47.98)的DST延迟时间更长。治疗前脱落率为26.9%(82/305)。老年人、非本地居住患者以及2018年前登记的患者更有可能拒绝耐多药/利福平耐药治疗。然而,在内勤/失业人员以及农民/渔民中,复发患者倾向于积极采取治疗措施。成功治疗率为62.1%(105/169)。老年人、合并糖尿病以及痰涂片转阴时间>1个月可能导致治疗结果较差。应立即采取干预措施,畅通诊断和治疗途径,并进一步完善社会保护措施,以鼓励患者积极配合治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44e3/9964905/a8624d46ff88/tropicalmed-08-00079-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验